6,678 trials
Aspergillosis · Candidemia
Primary: Plasma Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) — 6.56; 5.32 ug/mL
Asthma
Primary: Asthma Control Questionnaire (ACQ) — 328; 159; 96; 91 Participants — p=<0.001
Atrial Flutter
Primary: Duration of Energy Application — 10.2; 10.9 minute — p=0.25
Eating Disorders
Primary: Change From Baseline in Weight (Lbs.) at 12 Weeks — 2.2; -1.2 lbs
Elderly · Memory Impairment
Primary: Improvement of Cognitive Performance (Change From Baseline in Neuropsychological Computerized Test) — 3.46; 13.19; 7.92; 9.19 Points on a scale
Dry Eye Syndromes
Primary: Conjunctival Staining by Lissamine Green — 50.0; 53.8; 17.5; 15.4 Percentage of Participants
Bacterial Conjunctivitis
Primary: Susceptability Changes in Streptococcus Pneumoniae Distal to the Site of Instillation — 0; 0; 0; 0 Percent of resistant isolates
Schizophrenia · Schizoaffective Disorder
Primary: Change From Baseline in Weight at Week 16 — -1.09; -0.73 kilogram
Herpes Zoster
Primary: Serious Adverse Events Reported Within 42 Days Postvaccination — 84; 67; 2; 0 Participants
Allergic Rhinitis
Primary: Product Preference Questionnaire for Immediate Taste — 26.47; 10.78; 5.88; 15.69 Percentage of participants
Ocular Hypertension · Open Angle Glaucoma
Primary: Change in Glaucoma Symptom Scale (GSS)-SYMP-6 Score — 1.7; 3.2 Units on a Scale — p=0.001
Stroke · Depression
Primary: Twelve Week Depression Outcomes — 10.6 HAM-D depression score
Diabetes Mellitus
Primary: Number of Subjects With Decline in Forced Expiratory Volume (FEV1) Exceeding 20% From Baseline — 100; 112; 81; 105 participants
Hypercholesterolemia
Primary: Percent Change in Plasma Low Density Lipoprotein-cholesterol (LDL-C) From Day 1 (Study Baseline) to Week 8. — 2.9; -3.7; -10.6 percent change from baseline — p=0.1122
Parkinson Disease
Primary: Change From Baseline in the Blinded Rater Unified Parkinson's Disease Rating Scale (UPDRS) Total Score at Month 15 — 0.3; 0.7 Units on a scale — p=0.6503